Fiche centre
AA Medical Research Center
Flint — United States
Essais liés4clinical trials
VilleFlintlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07517263
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| QCZ484 | Hypertension | Phase 2 | NCT06857955 | A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients | ACTIVE_NOT_RECRUITING |
| Kerendia (Finerenone, BAY94-8862) | Maladie rénale chronique | À vérifier | NCT05348733 | A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | ACTIVE_NOT_RECRUITING |
| Pelacarsen (TQJ230) | Accident vasculaire cérébral | Phase 3 | NCT07517263 | An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) | ACTIVE_NOT_RECRUITING |